SSO# 4063 BSR - RESEARCH STUDY - DRUG EFFICACY RESEARCH STUDY USING CMS MEDICARE

国家老龄化研究所（NIA/NIH），行为和社会研究部（DBSR）寻求使用医疗保险和医疗补助服务中心（CMS）医疗保险D部分数据支持疗效研究。2003年的《医疗保险处方药、改进和现代化法案》（MMA）修订了《社会保障法》，通过医疗保险（D部分）向老年人提供处方药福利。新处方药福利的实施是自1965年成立以来医疗保险计划最重大的变化，可能对老年人的健康产生深远的影响。D部分数据为研究不同药物治疗或预防特定疾病的比较有效性提供了非常有价值的数据来源，因为这些数据包括可用于解决潜在偏倚的信息。药物计划提供者的信息将允许考虑这些变量，并有助于避免对数据的误解。然而，如果没有计划信息，就不可能确定接受每种比较药物的患者是否确实具有可比性，也不可能确定选择对疗效的影响。虽然大多数研究人员可以通过与CMS签订的标准数据使用协议获得大部分CMS Medicare Part D数据，但CMS于2008年5月发布的最终数据规则为Part D福利数据的分发制定了指导方针，限制了联邦机构及其承包商对计划数据的访问。该合同将允许研究人员，采取行动，以满足使命的NIA，进行有价值的分析药物的疗效，同时满足指南建立适当的数据使用CMS。

The National Institute on Aging (NIA/NIH), Division of Behavioral and Social Research (DBSR) seeks to support efficacy research using Center for Medicare and Medicaid Services (CMS) Medicare Part D data. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) amended the Social Security Act to provide prescription drug benefits to seniors through Medicare (Part D). The implementation of the new prescription drug benefit is the most significant change to the Medicare program since its inception in 1965 and could have profound effects on the health of the elderly. Part D data provide an exceptionally valuable source of data for research on the comparative effectiveness of different drugs for treatment or prevention of a particular condition because the data include information that can be used to address potential biases. Drug plan provider information would allow consideration of such variables and could help to avoid misinterpretations of data. However, without plan information, it would not be possible to determine whether the patients who received each of the drugs being compared were indeed comparable and determine the impact of selection on efficacy. While most researchers can gain access to the majority of CMS Medicare Part D data through standard Data Use Agreements with CMS, the Final Data Rule published by CMS in May 2008 that established guidelines for the distribution of Part D benefit data limits access to plan data to federal agencies and their contractors. The contract will allow researchers, acting to meet the mission of NIA, to conduct valuable analyses on drug efficacy while meeting the guidelines established for appropriate data use by CMS.